BioCentury
ARTICLE | Financial News

J&J reports first simeprevir sales

April 15, 2014 11:30 PM UTC

Johnson & Johnson (NYSE:JNJ) reported 1Q14 earnings on Tuesday, including $354 million in worldwide sales of Olysio simeprevir in the HCV drug's first full quarter of sales. U.S. sales of the drug were $291 million for the quarter. The pharma launched the HCV NS3/4A protease inhibitor in the U.S., Canada and Japan in December. J&J's Janssen Research & Development LLC unit has ex-Nordic rights to develop and commercialize simeprevir from Medivir AB (SSE:MVIR B), which was up SEK1.25 to SEK108.25 on Tuesday. ...